Supernus Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Pharma (SUPN) Tops Q2 EPS by 3c, Revenues Miss; Offers Revised FY19 Revenues Guidance Below Consensus
August 6, 2019 4:56 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.61, $0.03 better than the analyst estimate of $0.58. Revenue for the quarter came in at $104.7 million versus the consensus estimate of $109.7 million.
Total revenue of $104.7 million, a 5.2% increase over 2018Net product sales of $102.4 million, a 5.5% increase over 2018Operating earnings of $42.6 million, a 19.3% increase over 2018Submission of New Drug Application for SPN-812 on track for the second half of 2019Revising full year 2019 net product... More